How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Left Atrial Appendage (LAA) Closure Devices Market
- By Device Type: Watchman Device, Amplatzer Cardiac Plug (ACP), Amulet Device, Lariat Device, WaveCrest Device
- By Procedure Type: Percutaneous LAA Closure, Surgical LAA Closure
- By End User: Hospitals, Cardiac Specialty Clinics, Ambulatory Surgical Centers
- By Indication: Non-valvular Atrial Fibrillation, Stroke Prevention in Atrial Fibrillation Patients, Contraindication to Oral Anticoagulants
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Watchman Device leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 263 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.159 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.167 →
Full report · locked preview
Everything inside the Left Atrial Appendage (LAA) Closure Devices Market report
A complete, evidence-based study - 11 chapters and 110 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Device Type 5
Procedure Type 2
End User 3
Indication 3
Companies profiled
Boston Scientific Corporation
Abbott Laboratories
SentreHEART Inc.
Lifetech Scientific Corporation
AtriCure Inc.
CardioKinetix Inc.
Biosense Webster Inc.
MicroPort Scientific Corporation
Lepu Medical Technology (Beijing) Co. Ltd.
Shanghai Shape Memory Alloy Co. Ltd.
Zhejiang Aorui Medical Technology Co. Ltd.
LivaNova PLC
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →SentreHEART Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Lifetech Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AtriCure Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →CardioKinetix Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Biosense Webster Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →MicroPort Scientific Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Lepu Medical Technology (Beijing) Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Shanghai Shape Memory Alloy Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Zhejiang Aorui Medical Technology Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →LivaNova PLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →CardioFocus Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Edwards Lifesciences Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,057M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Watchman Device44.1
- Amplatzer Cardiac Plug (ACP)18.1
- Amulet Device11.0
- Lariat Device10.5
- WaveCrest Device16.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,527M → $2,081M · 3.9%
Europe$1,064M → $1,493M · 4.3%
Asia Pacific$971.4M → $1,568M · 6.2%
Latin America$601.4M → $812.8M · 3.8%
Middle East and Africa$462.6M → $756.1M · 6.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.382026
5.402027
5.402028
5.412029
5.432030
5.442031
5.442032
5.462033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boston Scientific Corporation24.3
- Abbott Laboratories15.6
- SentreHEART Inc.6.7
- Lifetech Scientific Corporation9.9
- AtriCure Inc.5.5
- CardioKinetix Inc.10.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type25.6%
Procedure Type23.8%
End User37.5%
Indication13.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.0
- Europe22.2
- Asia Pacific23.4
- Latin America12.1
- Middle East and Africa11.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 94 | 90 | 86 | 80 | 85 | 82 | 86 |
| Abbott Laboratories | 82 | 77 | 85 | 76 | 91 | 71 | 80 |
| SentreHEART Inc. | 85 | 67 | 63 | 80 | 79 | 74 | 75 |
| Lifetech Scientific Corporation | 68 | 82 | 64 | 81 | 78 | 80 | 76 |
| AtriCure Inc. | 59 | 74 | 69 | 73 | 67 | 62 | 67 |
| CardioKinetix Inc. | 51 | 46 | 62 | 58 | 67 | 62 | 58 |
| Biosense Webster Inc. | 61 | 55 | 54 | 43 | 62 | 44 | 53 |
| MicroPort Scientific Corporation | 57 | 37 | 55 | 50 | 45 | 56 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boston Scientific Corporation
- Abbott Laboratories
- SentreHEART Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Abbott Laboratories | ◐ | ✓ | ◐ | ✓ | ✓ | − |
| SentreHEART Inc. | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Lifetech Scientific Corporation | ◐ | ✓ | − | ✓ | ✓ | ✓ |
| AtriCure Inc. | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| CardioKinetix Inc. | ◐ | − | ◐ | ◐ | ◐ | − |
| Biosense Webster Inc. | ✓ | ◐ | ◐ | − | − | − |
| MicroPort Scientific Corporation | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Boston Scientific Corporation86
2Abbott Laboratories80
3Lifetech Scientific Corporation76
4SentreHEART Inc.75
5AtriCure Inc.67
6CardioKinetix Inc.58
7Biosense Webster Inc.53
8MicroPort Scientific Corporation50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Boston Scientific CorporationAbbott Laboratories
Challenger3
Strong scale, closing on the leaders.
SentreHEART Inc.Lifetech Scientific CorporationAtriCure Inc.
Contender1
Focused players with pockets of strength.
CardioKinetix Inc.
Niche2
Specialists in a single segment or region.
Biosense Webster Inc.MicroPort Scientific Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Device Type in North America, then scale across Left Atrial Appendage (LAA) Closure Devices Market — a $209M beachhead inside a $3.51B market.
Beachhead (SOM)$209Mobtainable near-term
Serviceable (SAM)$1.33Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Watchman Device
Best fit — highest urgency & budget in Device Type.
Economic buyer80 fit
Amplatzer Cardiac Plug (ACP)
Strong fit — clear ROI and a fast path to value.
End user66 fit
Amulet Device
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Procedure Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel26%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Left Atrial Appendage (LAA) Closure Devices Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified22%
Evaluation12%
Closed-won7%
$14.9KCAC
$78KLTV
5.3:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Left Atrial Appendage (LAA) Closure Devices Market is a resilient opportunity — $7.85B by 2033, compounding at 5.6%.
TAM · 2025$5.09Btoday
TAM · 2033$7.85Bforecast
CAGR5.6%2027–2033
Cumulative$57.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.85BTotal addressable market
SAM$2.99BServiceable available market
SOM$538MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.6% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.85BLarge & growingTAM by 2033 at 5.6% CAGR
$2.99BServiceable nowreachable with today’s model
$538MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.12BBear3.6% CAGR
$7.85BBase5.6% CAGR
$10.0BBull7.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Procedure Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Left Atrial Appendage (LAA) Closure Devices Market — a $9.91B market by 2033. Plan: grow share from 8.6% to 15.4%.
Market size · 2033$9.91Btotal addressable
Market CAGR9.2%2027–2033
Target share15.4%from 8.6% today
Revenue ambition$1.53Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.6% | 15.4% | At risk |
| Revenue | $838M | $1.53B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 37.7% | 40.5% | On track |
| Customer retention | 86.1% | 96.8% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Procedure Type capability
A defensible second engine — invest in Procedure Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Procedure Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $219M capacity & capability investment
- Greenlight bolt-on M&A in Procedure Type
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Left Atrial Appendage (LAA) Closure Devices Market conversation — a $9.56B market you can size, segment and defend in minutes.
Market size · 2033$9.56Btotal opportunity
Growth10.5%CAGR to 2033
Addressable buyers1,261+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 3 mopayback period
$45K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Boston Scientific CorporationAbbott LaboratoriesSentreHEART Inc.Lifetech Scientific CorporationAtriCure Inc.CardioKinetix Inc.Biosense Webster Inc.MicroPort Scientific Corporation+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Left Atrial Appendage (LAA) Closure Devices Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Left Atrial Appendage (LAA) Closure Devices Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Anti-Microbial Filter Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportIntubation Tube Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportAntimicrobial Film Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportInferior Vena Cava (IVC) Filter Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportAntimicrobial Face Masks Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportImplantable Loop Recorder Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportGynecological Devices Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportGynecological Surgical Devices Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportNeonatal (Preterm) Infant Care Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportAntimicrobial Efficacy Testing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportSyringes (Disposable and Reusable) Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportAntimicrobial Dressing Textiles Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.